NYSE - Delayed Quote USD

Novo Nordisk A/S (NVO)

126.85 +1.06 (+0.84%)
At close: April 26 at 4:00 PM EDT
127.30 +0.45 (+0.35%)
After hours: April 26 at 7:59 PM EDT

Key Executives

Amounts are as of December 31, 2022 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.
NameTitlePayExercisedYear Born
Mr. Lars Fruergaard Jorgensen President, CEO & Member of Management Board 4.65M -- 1966
Mr. Karsten Munk Knudsen Executive VP, CFO & Member of the Management Board 1.84M -- 1971
Mr. Henrik Ehlers Wulff Executive VP of Product Supply, Quality & IT and Member of the Management Board 1.86M -- 1970
Ms. Camilla Sylvest Executive VP of Commercial Strategy & Corporate Affairs and Member of the Management Board 1.81M -- 1972
Dr. Martin Holst Lange Executive VP of Development & Member of the Management Board 1.75M -- 1970
Dr. Marcus Schindler Ph.D. EVP of Research & Early Development, Chief Scientific Officer & Member of the Management Board 1.75M -- 1966
Mr. Maziar Mike Doustdar Executive VP of International Operations & Member of the Management Board -- -- 1970
Mr. Douglas J. Langa Executive VP of North America Operations & Member of Management Board -- -- 1966
Mr. Ludovic Helfgott Executive VP, Head of Rare Disease & Member of Management Board -- -- 1974
Ms. Tania Sabroe Executive VP of Global People & Organisation and Member of Management Board -- -- 1977

Novo Nordisk A/S

Novo Alle 1
Bagsvaerd, 2880
Denmark
45 44 44 88 88 https://www.novonordisk.com
Sector: 
Healthcare
Industry: 
Biotechnology
Full Time Employees: 
63,370

Description

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease. The Diabetes and Obesity care segment provides products for diabetes, obesity, cardiovascular, and other emerging therapy areas. The Rare Disease segment offers products in the areas of rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company also provides insulin pens, growth hormone pens, and injection needles. In addition, it offers smart solutions for diabetes treatment, such as smart insulin pens and Dose Check, an insulin dose guidance application. The company has a collaboration agreement with Aspen Pharmaceuticals to produce insulin products. Novo Nordisk A/S was founded in 1923 and is headquartered in Bagsvaerd, Denmark.

Corporate Governance

Novo Nordisk A/S’s ISS Governance QualityScore as of April 1, 2024 is 1. The pillar scores are Audit: 2; Board: 2; Shareholder Rights: 9; Compensation: 1.
Corporate governance scores courtesy of Institutional Shareholder Services (ISS) Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.

Recent Events

  • Apr 22, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 17, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 08, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing
  • Apr 02, 2024
    Dividend Date
  • Apr 01, 2024
    6-K: Corporate Changes & Voting Matters
    See Full Filing

Upcoming Events

Related Tickers

VKTX Viking Therapeutics, Inc.
74.31
+7.91%
 
VRTX Vertex Pharmaceuticals Incorporated
397.48
-0.06%
 
MRNA Moderna, Inc.
107.97
+1.69%
 
CRSP CRISPR Therapeutics AG
53.91
+0.34%
 
RXRX Recursion Pharmaceuticals, Inc.
8.12
+3.57%
 
REGN Regeneron Pharmaceuticals, Inc.
883.20
-0.84%
 
IBRX ImmunityBio, Inc.
7.35
+43.84%
 
ALT Altimmune, Inc.
7.26
+0.83%
 
NVAX Novavax, Inc.
4.0900
+3.54%
 
MDGL Madrigal Pharmaceuticals, Inc.
193.33
-0.54%